- Porton Pharma Solutions and Jianxiang Bioscience have launched a strategic partnership to provide end-to-end peptide drug development and commercial manufacturing services.
- The collaboration combines Porton’s R&D capabilities with Jianxiang’s large-scale manufacturing infrastructure to support global peptide API supply.
Porton Pharma Solutions Ltd. has entered into a strategic partnership with Hubei Jianxiang Bioscience Co., Ltd. to deliver integrated peptide drug development and contract manufacturing services. The collaboration will focus on building a one-stop service system covering development through to commercial manufacturing of peptide active pharmaceutical ingredients (APIs) and intermediates.
The partnership brings together Porton’s capabilities in research, process development, and regulatory-compliant manufacturing with Jianxiang’s commercial-scale production capacity. Jianxiang operates 10 production lines and pilot plants designed to meet cGMP standards set by the U.S. FDA, EMA, and NMPA, supporting large-scale global supply.
According to the companies, the collaboration is intended to integrate R&D resources, technical expertise, and manufacturing capabilities to improve delivery efficiency and provide scalable solutions for peptide drug production. The combined platform will offer end-to-end Chemistry, Manufacturing and Controls (CMC) services across the drug lifecycle, with the aim of reducing development timelines and overall project costs.
Porton stated that its existing infrastructure, including R&D centres and GMP manufacturing facilities in Shanghai and Chongqing, will support early-stage development and process optimisation. Jianxiang will contribute manufacturing capacity for commercial-scale production, forming a coordinated supply chain model for peptide APIs and intermediates.
The companies said the partnership is designed to strengthen their position in the peptide drug sector by aligning front-end development with back-end manufacturing, enabling pharmaceutical clients to access integrated CDMO and contract manufacturing services for peptide-based therapies.
